Meeting
2019 ASCO Annual Meeting
Apatinib for locoregionally recurrent or metastatic nasopharyngeal carcinoma after failure of first-line chemotherapy: A multicenter, phase II trial.
Authors
Wei Jiang
Affiliated Hospital of Guilin Medical University, Guilin, China
Wei Jiang , Jinghui Liang , Yufei Pan , Xiaolan Ruan , Rui Cai , Zhuokai He , Qiuqiu Chen , Rongjun Zhang , Xi Yang , Meilian Liu , Bo Zhao , Zhengchun Liu , Zhijie Niu
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Head and Neck Cancer
Track
Head and Neck Cancer
Sub Track
Advanced/Metastatic Disease
Clinical Trial Registration Number
NCT03130270
Citation
J Clin Oncol 37, 2019 (suppl; abstr 6030)
DOI
10.1200/JCO.2019.37.15_suppl.6030
Abstract #
6030
Poster Bd #
19
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
Penpulimab plus anlotinib in patients with recurrent or metastatic head and neck squamous cell carcinoma after the failure of first-line platinum-based chemotherapy: A single-arm, multicenter, phase 2 study.
First Author: Changgong Zhang
Poster
2019 ASCO Annual Meeting
A phase II, open label, multicenter trial of avelumab in patients with advanced, metastatic high-grade neuroendocrine carcinomas NEC G3 (WHO 2010) progressive after first-line chemotherapy (AVENEC).
First Author: Christian Fottner
Poster
2013 ASCO Annual Meeting
PARTNER: A randomized phase II study of docetaxel/cisplatin (doc/cis) chemotherapy with or without panitumumab (pmab) as first‑line treatment (tx) for recurrent or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN).
First Author: Lori J. Wirth
Poster
2013 Gastrointestinal Cancers Symposium
Class III β-tubulin as a predictive marker for taxane-based first-line palliative chemotherapy in recurrent or metastatic gastric cancer.
First Author: Jun-Eul Hwang